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Abstract: Ophthalmic bromfenac sodium sesquihydrate is a topically applied selective 
  cyclooxygenase (COX)-2 inhibitor. It is similar to amfenac, except for a bromine atom at 
the C4 of the benzoyl ring position, which markedly affects its in vitro and in vivo potency, 
extends the duration of anti-inflammatory activity, and enhances its inhibitory effect on COX-2 
  absorption across the cornea and penetration into ocular tissues. The United States Food and Drug 
  Administration approved bromfenac in 2005 for the treatment of postoperative inflammation 
and the reduction of ocular pain in patients who have undergone cataract surgery. Nonsteroidal 
anti-inflammatory drugs (NSAIDs), and among them bromfenac, could be even more effective 
than steroids at reestablishing the blood–aqueous barrier, as revealed by flare on slit-lamp exami-
nation and as quantitatively measured using ocular fluorophotometry. Similar to other NSAIDs, 
it has a role in inhibiting intraoperative miosis during cataract surgery.   However, bromfenac 
also seems to be useful in other situations, such as refractive surgery, allergic   conjunctivitis 
(not useful in dry eye), choroidal neovascularization, and even ocular oncology. No reports of 
systemic toxicity have been published and bromfenac has good topical tolerance with a low 
incidence of adverse effects.
Keywords: bromfenac, ophthalmic nonsteroidal anti-inflammatory drugs, inflammation, 
cataract surgery
Bromfenac sodium sesquihydrate
Molecule
Bromfenac sodium sesquihydrate, also denominated as sodium 2-amino-3-(4-
bromobenzoyl) phenylacetate sesquihydrate, has a molecular weight of 766.34 and a 
molecular formula of C30H28Br2 N2 Na2O9 (Figure 1). The chemical structure is similar 
to amfenac, except for the addition of a bromine atom at the C4 of the benzoyl ring 
position. Containing a halogen in its structure enhances the molecule’s lipophilicity, 
thereby facilitating absorption across ocular tissues. The bromine atom of bromfenac 
has a marked effect on its in vitro and in vivo potency, extends the duration of anti-
inflammatory activity, and enhances its inhibitory effect on cyclooxygenase (COX)-2 
absorption across the cornea and penetration into ocular tissues.1,2
Mechanism of action
Bromfenac, a nonsteroidal anti-inflammatory drug (NSAID), has anti-inflammatory 
activity thought to be due to its ability to block prostaglandin synthesis by inhibit-
ing COXs, an important group of enzymes active in the inflammatory process, 
which catalyzes the biosynthesis of eicosanoids from arachidonic acid to produce 
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in humans is unknown. Based on the maximum proposed 
dose of one drop in each eye (0.09 mg) and pharmacoki-
netic information from other routes of administration, the 
systemic concentration of bromfenac is estimated to be 
below the limit of quantification (50 ng/mL) at steady-state 
in humans.9
Studies evaluating the pharmacokinetic profile of   topical 
bromfenac 0.09% revealed a maximum concentration of 
95.3 ng/g in the aqueous humor after instillation of a single 
dose in rabbits.10 The time to maximum   concentration in the 
aqueous humor in both studies was 2 hours.10,11 The half-life 
was 2.2 hours, but the drug remained detectable at 
24 hours.10,11 In a separate multi-dose study, rabbits received 
one drop of bromfenac 0.09% three times daily for 14 days. 
The bromfenac concentration was 1103.0 ± 424.2 ng/g in the 
sclera; 78.1 ± 13.0 ng/g in the choroid; 32.4 ± 5.4 ng/g in the 
retina; 1.3 ± 0.2 ng/g in the vitreous; and 55.9 ± 9.2 ng/g in 
the aqueous humor.10
Human studies have revealed that the drug concentration 
required to reduce human COX-2 activity to half maximal 
(IC50) was achieved after a single dose of bromfenac,12 and 
the concentration of bromfenac in the aqueous humor of 
patients undergoing cataract surgery, after the instillation 
of one drop of bromfenac 12 hours prior to surgery, was in 
excess of the IC50 value for COX-2, but not the IC50 value 
for COX-1.13
Ocular commercial presentations
Bromfenac sodium ophthalmic solution 0.1% was first 
approved in 2000 as Bronuck® (Senju Pharmaceutical 
Company, Ltd, Osaka, Japan) and is currently approved 
for the clinical indications of the treatment of postoperative 
  inflammation, blepharitis, conjunctivitis, and scleritis.14 The 
same formulation was approved in the United States in 2005 
as XibromTM 0.09% (Ista Pharmaceuticals Inc, Irvine, CA) for 
the treatment of postoperative inflammation and the   reduction 
of ocular pain in patients who have   undergone cataract 
surgery. However, it has been unavailable since February 
20119 because in October 2010, BromdayTM 0.09% (Ista 
  Pharmaceuticals Inc) was approved by the Food and Drug 
Administration (FDA) as the first once-daily   ophthalmic 
NSAID for the treatment of postoperative ocular inflamma-
tion and the reduction of ocular pain after cataract surgery.15 
A generic formulation in 2011 was approved in the United 
States by Coastal Pharms. In Europe, Yellox™ 0.09% (Croma 
Pharma, GmbH, Leobendorf, Austria) was approved in 
2011 for the treatment of postoperative ocular inflammation 
  following cataract extraction in adults.16
prostaglandins (PG) and thromboxanes.1 Prostaglandins 
are mediators of certain kinds of intraocular inflammation. 
In studies of   animal eyes, PG have been shown to disrupt 
the blood–aqueous humor barrier and increase vascular 
permeability, vasodilatation, intraocular pressure, and 
leukocytosis.3,4
Two cyclooxygenases (COX-1 and COX-2) encoded 
by two different genes have been cloned and character-
ized.5,6 Although COX-1 and COX-2 share a high level 
of   homology (65%), the activity and expression of these 
enzymes are regulated differentially, and they can   function 
independently within the same cell type.7 COX-1 is 
important for homeostatic functions, such as maintaining 
the integrity of the gastrointestinal mucosa, mediating 
platelet function, and regulating renal blood flow. COX-2 
is often induced at sites of inflammation. Animal   models 
have shown that COX-2 is the primary mediator for 
ocular inflammation.3 Therefore, inhibition of COX-2 is 
thought to be the most important therapeutic mechanism 
of   ophthalmic NSAIDs.
NSAIDs have different relative potencies against COX-1 
and COX-2. Bromfenac has been shown to be the most potent 
ophthalmic NSAID in inhibiting the COX-2 enzyme.4 It was 
approximately 32 times more active against COX-2 than 
COX-1 in a rabbit model and 18 times more potent than 
ketorolac in inhibiting COX-2.8
Ocular pharmacokinetics
The plasma concentration of bromfenac following ocular 
administration of bromfenac 0.09% ophthalmic solution 
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Figure 1 Molecular structure of bromfenac sodium sesquihydrate.
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Once-daily dose
Several studies have found that ophthalmic medications 
dosed less frequently tend to yield improved compliance and 
patient satisfaction.17 The benefits of less frequent dosing also 
include less exposure to benzalkonium chloride and a lower 
potential for adverse effects.18,19
Based on previous studies, which showed detectable 
concentrations of bromfenac at 24 hours after a single 
dose,10–12 the possibility of bromfenac 0.09% dosed once 
daily was studied.
Overall, bromfenac ophthalmic solution 0.09% dosed 
once a day appeared to be as effective as when dosed twice 
a day in treating post-cataract surgery anterior chamber 
  inflammation, although no direct comparisons were made and 
the designs of the clinical trials were different.20,21 However, 
there are no studies determining the efficacy of once-daily 
doses in the treatment of posterior segment inflammation.
Adverse effects of ophthalmic 
bromfenac
Systemic adverse effects
Oral bromfenac was initially approved for the treatment 
of short-term pain in 1997.22 However, cases of fulminant 
hepatic failure were reported after prolonged use, and it was 
withdrawn from the market in 1998.23,24 Although the plasma 
concentration of bromfenac following ocular administra-
tion of bromfenac 0.09% ophthalmic solution in humans is 
unknown, it is supposed to be below the limit of quantifica-
tion (50 ng/mL) and no reports of systemic toxicity have 
been published.9
Shiffman et al25 also confirmed the systemic safety. 
They showed normal liver function test values for more than 
90% of subjects and no evidence of hepatic toxicity after 
14 days of twice-daily dosing of topical bromfenac.18
Although exacerbation of asthmatic symptoms has been 
reported with the use of topical NSAIDs, such as diclofenac 
or indomethacin, these events have not been described with 
the use of topical bromfenac.26,27
Ocular adverse effects
The rate of serious ocular adverse events, reported 6 years 
after the use of topical bromfenac in one study, was 
0.0002%.18 These serious ocular adverse events included 
five corneal ulcers, three corneal erosions, three corneal 
perforations, three corneal infiltrates, and two cases of 
corneal thinning.18 The most commonly reported adverse 
effects in the Phase III clinical trials of topical bromfenac 
included iritis, an abnormal sensation in the eye, eye pain, 
eye pruritus, headache, eye irritation (burning/stinging), and 
conjunctival hyperemia.18
The adverse effects of bromfenac eye drops in the ocular 
surface have been described as being particularly associated 
with the preservatives used in ophthalmic solutions, such 
as benzalkonium chloride. However, the experimental use 
of preservative-free bromfenac (commercially unavailable) 
also exhibited considerable toxicity in corneoconjunctival 
cell lines.28 In contrast, in Phase III clinical trials of topi-
cal bromfenac, safety assessments for subjects treated with 
bromfenac were generally equivalent to or better than those 
for subjects treated with a vehicle.18 Animal studies have 
implicated NSAIDs in delaying corneal wound healing29 
and decreasing the migration of corneal epithelium.30 There 
are four reported cases of corneal melting and subsequent 
perforation in one of them after topical bromfenac use.31,32 
In three of the reported cases of bromfenac-induced melting, 
the patients had severe ocular surface compromise. A role 
for metalloproteinase (MMP)-1 and MMP-8 has been 
proposed in NSAID-induced melting. An increase in MMP-1 
and MMP-8 expression in eyes treated with diclofenac has 
been reported.33 Proteases play an important role in corneal 
degradation and NSAID use may be implicated in their 
overexpression.
One study assessed the effects of topical bromfenac in 
human corneal endothelial cells, and revealed it was unlikely 
to cause endothelium damage at the concentration used under 
the usual conditions.28
Bromfenac in cataract surgery
NSAIDs are one of the most commonly prescribed classes 
of medications worldwide. Aspirin and other chemically 
related compounds, the properties of which in oral presenta-
tions have been well known for many decades, have recently 
been prepared in topical ophthalmic formulations. Systemic 
indications are due to their analgesic, antipyretic, and anti-
inflammatory properties.
In the United States, bromfenac ophthalmic solution 
0.09% (XibromTM; Ista Pharmaceuticals Inc) was approved 
by the US Food and Drug Administration (FDA) in 2005 
for the treatment of postoperative inflammation and the 
r  eduction of ocular pain in patients who have undergone 
cataract surgery.9
Mydriasis maintenance during surgery
Topical NSAIDs are FDA-approved for the inhibition of 
intraoperative miosis during cataract surgery. Several clinical 
studies have demonstrated similar mydriatic properties for 
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diclofenac 0.1%,34,35 ketorolac 0.4% and 0.5%,36,37   suprofen 
1%,38,39 flurbiprofen 0.03%,35 and bromfenac 0.09%.40 
However, the effectiveness of topical NSAIDs on pupil 
size in vitreoretinal surgery appears to vary from one study 
to another.39
Reducing postoperative inflammation  
in cataract surgery
There is evidence that topical NSAIDs are capable of reducing 
postoperative inflammation after cataract surgery38,39 when 
used correctly and cause no significant side effects or toxic-
ity.41–44 However, there are only four FDA-approved drugs for 
this use: diclofenac, ketorolac, nepafenac, and bromfenac. 
Although studies comparing NSAIDs to corticosteroids 
have not revealed differences in the reduction of intraocular 
inflammation after cataract surgery,42,45–47 NSAIDs appear to 
be more effective at reestablishing the blood–aqueous barrier, 
as revealed by flare on slit-lamp examination and as quanti-
tatively measured using ocular fluorophotometry.38,39,42,48 This 
is true for both bromfenac presentations currently available 
in the USA.20,21,40,49,50 Bromfenac has not been demonstrated 
to be superior to ketorolac in reducing the inflammation rate, 
but the incidence of corneal epitheliopathy was reported to 
be significantly higher.18 Takamatsu et al and Ohara et al’s 
case series comparing bromfenac and diclofenac drops after 
cataract extraction did not show any differences in the inflam-
mation rate on days 7 and 28, respectively.51,52
Masuda et al compared several concentrations of twice-
daily 0.01%, 0.1%, and 0.2% bromfenac drops in 228 cataract 
cases. The 0.1% and 0.2% solutions showed superior anti-
inflammatory activity in contrast to the 0.01% solution. There 
were no adverse events that were concentration-dependent; 
thus, 0.1% bromfenac was deemed optimal to minimize any 
potential for corneal toxicity.53
Both once- and twice-daily dosing of bromfenac have 
been demonstrated to be beneficial for patients with a low 
rate of compliance or who need to minimize exposure to 
medications and excipients.18,20 However, efficacy data 
from clinical trials of bromfenac 0.09% with once-daily 
dosing cannot be directly compared to twice-daily dosing 
because the protocols for these clinical trials differ in terms 
of the predosing criteria and the Summed Ocular Inflam-
mation Score (SOIS) end point scales used.21 Both dosing 
presentations achieved the prespecified efficacy end points 
of their respective clinical trials and were thus effective in 
comparison to the placebo group.
Miyanaga et al compared topical bromfenac to a topical 
  steroid or a combination in 72 patients following cataract 
  surgery.54 They did not find any significant difference in anterior 
chamber inflammation in this case series. There is no recent 
larger controlled trial comparing the efficacy of bromfenac 
alone versus a steroid or a combination in cataract surgery. 
There are no publications about using bromfenac in glaucoma, 
strabismus, or vitreoretinal surgeries to reduce inflammation.
Reducing ocular pain in cataract surgery
Among subjects who experienced ocular pain after surgery, 
the median time for resolution of pain was 2 days for those 
treated with bromfenac compared with 5 days for those 
treated with a vehicle. The proportion of subjects who 
were pain-free was statistically significantly greater for 
the   bromfenac group than for the vehicle group over all 
  visits.55,56 In January 2006, the FDA expanded the indication 
for   bromfenac to include the reduction of ocular pain after 
cataract surgery on the basis of these results.
Cystoid macular edema
Cystoid macular edema (CME) remains the most common cause 
of vision loss after cataract surgery, with up to 58% of patients 
being reported to have some angiographic evidence of CME.57 
On the other hand, the rate of clinically evident CME was much 
lower at 4.7% in those treated with a placebo and 1.8% in those 
treated with steroids.18 Currently, there is no FDA-approved 
treatment for the prevention or treatment of CME following 
cataract surgery. However, reviewing the world literature, 
Rossetti et al determined from a meta-analysis that the preven-
tion and treatment of CME with NSAIDs is beneficial.58
It remains unclear whether prophylactic treatment pre-
vents the onset of chronic CME or in some way decreases 
its severity. Therefore, the long-term benefit of prophylactic 
treatment remains unproven, making this FDA-unapproved 
indication controversial.59
Other ophthalmic uses of bromfenac
NSAIDs have increasingly been included in the therapeutic 
arsenal in ophthalmology. The treatment of intraocular 
inflammation and pain after cataract surgery and the treat-
ment and prevention of cystoid macular edema are the main 
indications. However, NSAIDs have also been suggested to 
have some effectiveness in some pathology, but with a more 
limited action than other available agents. Their use in these 
cases can be considered additional therapy.
Allergic conjunctivitis
The pathogenesis of allergic conjunctivitis is compli-
cated, but the mast cell and its chemical mediators are 
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probably the most important components. These media-
tors comprise a wide range of molecules, including many 
different PG. Among them, PGE1 and PGE2 diminish 
the threshold of itching and become NSAIDs in poten-
tial therapy for allergic conjunctivitis. Topical ketorolac 
0.5% is the only NSAID approved by the FDA for the 
relief of ocular itching in patients with seasonal allergic   
rhinoconjunctivitis.
In an experimental model, Hashimoto et al found that 
ketotifen was less effective in reducing PG than   bromfenac, 
but it reduced plasma exudation significantly more. 
  Moreover, ketotifen was much more effective in inhibiting 
the itch–scratch response than bromfenac.60
Miyake-Kashima et al compared bromfenac to the mast-
cell stabilizer, pemirolast potassium. Improvements in objec-
tive clinical findings were similar for both, and subjective 
symptoms after one week of twice-daily dosing did not show 
any improvement for either agent.61
Uchio et al evaluated the efficacy and safety of bromfenac 
0. 1% in the long-term management of vernal keratoconjunc-
tivitis patients while mast cell stabilizers and topical steroids 
were continued. They found that the role of bromfenac in 
these patients might be to suppress the trigger-inducing 
recurrence of the disease by controlling the COX pathways. 
Once vernal keratoconjunctivitis recurred, bromfenac could 
not reduce the severity of the disease.62
Ocular surface inflammatory diseases
Oral NSAIDs are used as first-line agents in scleritis and 
episcleritis with good results. However, topical presentations 
have not had the same results and are therefore infrequently 
used.63 There is evidence that NSAIDs are more useful in the 
treatment of inflamed pinguecula and pterygium compared 
to topical steroids.64
Dry eye
Inflammation was included in the new definition of dry eye 
given by the International Dry Eye Workshop.65 Inflamma-
tory mediators in the dry eye tear film are a potential target 
for molecules such as NSAIDs with lower side effects than 
topical corticosteroids. A recent study in a mouse model 
of dry eye raised the possibility that NSAIDs may help 
alleviate some of the signs and symptoms of ocular sur-
face disease.66 However, corneal melting and perforations 
have been reported with NSAIDs, even with bromfenac, 
which prevents routine use in dry eye patients for these 
potential adverse events, especially in cases with corneal 
involvement.31,67
Refractive surgery
Surface laser procedures remove the corneal epithelium 
in different ways (laser, manual debridement, diluted 
alcohol, epikeratome) prior to laser ablation of the stroma. 
  Regardless of which technique is used, laser reshaping 
of the cornea   damages the sensory nociceptive fibers. 
Patients can   experience various degrees of pain during the 
  epithelial   regeneration process, and NSAIDs are   effective in 
controlling it. Moreover, they have the additional benefit of 
reducing inflammation by inhibiting COX. In   ophthalmology, 
the primary topical analgesia used to control pain is 
NSAIDs and this medication has shown to be effective in 
  photorefractive keratectomy.68,69
Sher et al found no significant differences in discomfort 
and safety between topical bromfenac 0.09% and k  etorolac 
0.4%, approved by the FDA to control postoperative 
  photorefractive keratectomy ablation pain.69 However, Wang 
et al found there was less pain in eyes treated with bromfenac 
0.09% than in those treated with ketorolac 0.5% following 
LASEK or epi-LASEK surgery. There were no statistically 
significant differences in uncorrected visual acuity between 
groups.70
Diabetic retinopathy
Both animal and human studies have demonstrated ele-
vated levels of PG in eyes with diabetic retinopathy.71,72 
Therapeutic inhibition of COX-2 in the retina may now be 
achievable with both topical nepafenac 0.1% and bromfenac 
0.09%. The first one has demonstrated the ability to inhibit 
diabetes-induced retinal microvascular disease in animal 
models.73 Bromfenac may be as useful as nepafenac in 
animal models. However, there are no studies in humans 
and consequently, there is insufficient evidence to recom-
mend the use of NSAIDs as prophylaxis or for primary 
treatment of diabetic retinopathy or even diabetic macular 
edema. Furthermore, other routes, including periocular 
and intravitreal, are currently being investigated to achieve 
greater therapeutic effects.74,75
Age-related macular degeneration
Age-related macular degeneration is the leading cause of 
blindness in developed countries.76 While the etiology and 
pathogenesis of this disease are complex and remain poorly 
understood, there is evidence from human and animal stud-
ies that inflammatory and immunological events play a 
central role.77
COX-2 is a promoter of angiogenesis and can be detected 
in human choroidal neovascular membranes.78 Thus, the 
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inhibition of COX-2 by NSAIDs reduces vascular endothe-
lial growth factor production and directly inhibits choroidal 
neovascularization in both trauma-induced and ischemia-
induced animal models.74 In an experimental model, the use 
of topical bromfenac led to the translocation of Nrf2 and 
the induction of the antioxidant protein heme oxygenase 
(HO-1) in neovascularization lesions. The sizes of lesions 
were significantly smaller in the group of rats treated with 
bromfenac, indicating a potential therapeutic effect for 
intraocular angiogenic diseases.79 These findings can justify 
the results that showed bromfenac worked as an adjunctive 
therapy to intravitreal ranibizumab in a prospective ran-
domized controlled trial, showing a beneficial effect in the 
change of macular central thickness.80 However, Zweifel et al 
found no benefit to the addition of topical bromfenac 0.09% 
twice daily over 2 months for patients receiving monthly 
intravitreal antivascular endothelial growth factor; in fact, 
there was limited response in terms of reducing persistent 
exudation.81
At present, there is insufficient evidence to recommend 
NSAIDs for prophylaxis or treatment of age-related macular 
degeneration in human beings.
Ocular tumors
It is well known that systemic NSAIDs reduce the incidence 
of colon cancer by 40%–50%, and several epidemiologi-
cal, clinical, and experimental studies have established 
NSAIDs as promising cancer chemopreventive agents.82,83 
At the same time, COX-2 expression is increased in both 
uveal melanoma and retinoblastoma. Some COX-2 inhibi-
tors have been demonstrated in experimental studies to 
inhibit the proliferation of human retinoblastoma cell lines, 
limit the progression of uveal melanoma, and increase 
the radiosensitivity of uveal melanoma.84–87 Moreover, 
COX-2 expression appears to be correlated with tumor 
malignancy.88
Future studies about the therapeutic potential of 
NSAIDs in the treatment and prevention of ocular tumors 
are under way.
Method of literature search
In order to prepare this review, we conducted a Medline and 
PubMed search of the literature for the period between 2000 
and 2011 using the following key words, as well as various 
combinations of them: bromfenac, Xibrom, ophthalmic 
NSAIDs. Reference lists from the selected articles were 
used to obtain further relevant articles not included in the 
electronic database.
Disclosure
The authors report no proprietary or commercial interest 
in any product mentioned or concept discussed in this 
article.
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